News

AICUBE

Letter to Shareholders

Dear Shareholders,

I hope you are all doing well.

We have come to the end of this difficult and unexpected year navigating by sight among bans and restrictions. Each of us has dealt with the pandemic in our own way, often finding a safe haven in our families and closest friends.

In AICUBE we have tried not to lose the rhythm that we have imposed on ourselves since the beginning of our project in order to make such a great challenge a success.

In fact, the first part of the clinical trial at the University of Pavia (Dr. Rondanelli) in collaboration with the Italian Institute of Technology, the first phase called POC (Proof of Concept) of validation of the salivary glucose sensor has been concluded and we have started the next phase that will lead us to the industrialization of the sensor in 2021.

As you know in 2020 we have deliberated two capital increases that have allowed us to collect, among the shareholders, more than 500K € and to bring in new ones.

The subscription for new investors will close in January, but as of now I can confirm that two of them have already invested in AICUBE 100 K€.

During the pandemic the interest in salivary testing has grown tremendously. We have been contacted by two Italian pharmaceutical companies that are exploring the possibility to collaborate with us (NDA signed with both of them). We have given interviews to several newspapers, won some awards, proving that our vision of the future of non-communicable disease (NCD) and communicable disease prevention was correct.

We are very close to a preliminary agreement with a large multinational company in the "oral care" sector for a collaboration on the development of our device. I can't share anything yet, but if we were to close a deal with them, we would have a strong acceleration of the project, as well as grow the value of the company.

In January I will sign contracts with companies that, led by us, will work on design, microfluidics, electronics, cloud development and IOT.

In order to better coordinate all this, we have signed an agreement with Ing.Bosetto, a consultant with many years of experience in medical R&D.

We also started the long regulatory process for the necessary classification of our device by a notification body, always using a professional in the field.

In light of all these news, the optimism for the future of AICUBE grows even more, thanks also to the renewed confidence of you members, the entry of new investors and the strong interest of multinational companies in our business model.

I wish you a Merry Christmas.


AICUBE

participates in

SMAU 2020

Booth C32


AICUBE is among the finalists

of the Gaetano Prize

Marzotto



Interview with AICUBE

of

Ernst & Young


Linkedin

YouTube

Facebook

Interview on Le Fonti TV

AICUBE at The Next Unicorns on Le Fonti with CrowdFundMe

Il Life Science in Italia tra eccellenze produttive e nuove frontiere della ricerca

Interview with AICUBE